SAN FRANCISCO — Lining up with California courts, the U.S. Court of Appeals for the Federal Circuit ruled Monday that the Food, Drug & Cosmetic Act does not preempt private actors from using California law to crack down on unapproved drugs.
The ruling is a partial win for Allergan and its attorneys at Gibson, Dunn & Crutcher, who will now use it to prevent Athena Cosmetics from marketing in California a prostaglandin-based eyelash enhancer that has not been approved by the FDA.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
